New malaria study to open at NIHR Bristol CRF

The World Health Organisation (WHO) has recommended the use of the Oxford R21/Matrix-M™ malaria vaccine. Developed by the University of Oxford and the Serum Institute of India, it is only the second malaria vaccine recommended by the WHO.

R21/Matrix-M™ is already proving more effective than RTS,S, the first WHO-approved malaria vaccine, showing 75% effectiveness in four trial countries. It is also proving to be cheaper, costing between $2 and $4 per dose. Following further approvals, the vaccine could be rolled out as early as 2025 and is expected to help save the lives of millions of people.

Further information about previous work on the R21 vaccine can be found on the University of Oxford blogs and the Guardian website.

The NIHR Bristol Clinical Research Facility is hoping to open the Malaria R21 study in the coming months and is looking for healthy volunteers. The aim of the study will be to look at the body’s ability to promote an immune response to an increasing dose of the R21 vaccine.

For further information, please get in touch with the Vaccine and Testing Research team by phoning 0117 3421514 or completing our contact form.